JP2003530437A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003530437A5 JP2003530437A5 JP2001576021A JP2001576021A JP2003530437A5 JP 2003530437 A5 JP2003530437 A5 JP 2003530437A5 JP 2001576021 A JP2001576021 A JP 2001576021A JP 2001576021 A JP2001576021 A JP 2001576021A JP 2003530437 A5 JP2003530437 A5 JP 2003530437A5
- Authority
- JP
- Japan
- Prior art keywords
- beta
- modified
- substituent
- candidate
- derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 description 29
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 27
- 239000003795 chemical substances by application Substances 0.000 description 26
- 125000001424 substituent group Chemical group 0.000 description 24
- 239000000203 mixture Substances 0.000 description 22
- 239000000126 substance Substances 0.000 description 22
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 19
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical group O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 18
- 150000001735 carboxylic acids Chemical class 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 238000012986 modification Methods 0.000 description 12
- 230000004048 modification Effects 0.000 description 12
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- 229960000905 indomethacin Drugs 0.000 description 9
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 8
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 8
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 8
- 208000024827 Alzheimer disease Diseases 0.000 description 7
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 7
- IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 7
- 229960003803 meclofenamic acid Drugs 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- LFWHFZJPXXOYNR-RQZCQDPDSA-N 2-[(3e)-6-fluoro-2-methyl-3-[(4-methylsulfanylphenyl)methylidene]inden-1-yl]acetic acid Chemical compound C1=CC(SC)=CC=C1\C=C/1C2=CC=C(F)C=C2C(CC(O)=O)=C\1C LFWHFZJPXXOYNR-RQZCQDPDSA-N 0.000 description 6
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 6
- 229960002390 flurbiprofen Drugs 0.000 description 5
- 235000019260 propionic acid Nutrition 0.000 description 5
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 4
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 4
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 4
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 4
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 4
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 4
- 229960003184 carprofen Drugs 0.000 description 4
- 229960001419 fenoprofen Drugs 0.000 description 4
- 229960000894 sulindac Drugs 0.000 description 4
- 208000031124 Dementia Alzheimer type Diseases 0.000 description 3
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical group F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 3
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 3
- DCBDOYDVQJVXOH-UHFFFAOYSA-N azane;1h-indole Chemical compound N.C1=CC=C2NC=CC2=C1 DCBDOYDVQJVXOH-UHFFFAOYSA-N 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 125000002843 carboxylic acid group Chemical group 0.000 description 3
- 229960004369 flufenamic acid Drugs 0.000 description 3
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 3
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- FWKQNCXZGNBPFD-UHFFFAOYSA-N Guaiazulene Chemical compound CC(C)C1=CC=C(C)C2=CC=C(C)C2=C1 FWKQNCXZGNBPFD-UHFFFAOYSA-N 0.000 description 2
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- CNBGNNVCVSKAQZ-UHFFFAOYSA-N benzydamine Chemical compound C12=CC=CC=C2C(OCCCN(C)C)=NN1CC1=CC=CC=C1 CNBGNNVCVSKAQZ-UHFFFAOYSA-N 0.000 description 2
- 239000000544 cholinesterase inhibitor Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 2
- 229960000991 ketoprofen Drugs 0.000 description 2
- GXMBHQRROXQUJS-UHFFFAOYSA-N (2-hept-2-ynylsulfanylphenyl) acetate Chemical compound CCCCC#CCSC1=CC=CC=C1OC(C)=O GXMBHQRROXQUJS-UHFFFAOYSA-N 0.000 description 1
- WBSMIPAMAXNXFS-UHFFFAOYSA-N 5-Nitro-2-(3-phenylpropylamino)benzoic acid Chemical group OC(=O)C1=CC([N+]([O-])=O)=CC=C1NCCCC1=CC=CC=C1 WBSMIPAMAXNXFS-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical class NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 1
- 101000928278 Homo sapiens Natriuretic peptides B Proteins 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- KTDZCOWXCWUPEO-UHFFFAOYSA-N NS-398 Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1CCCCC1 KTDZCOWXCWUPEO-UHFFFAOYSA-N 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 102100036836 Natriuretic peptides B Human genes 0.000 description 1
- JZFPYUNJRRFVQU-UHFFFAOYSA-N Niflumic acid Chemical compound OC(=O)C1=CC=CN=C1NC1=CC=CC(C(F)(F)F)=C1 JZFPYUNJRRFVQU-UHFFFAOYSA-N 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- PQUGCKBLVKJMNT-UHFFFAOYSA-N SC560 Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=CC(C(F)(F)F)=N1 PQUGCKBLVKJMNT-UHFFFAOYSA-N 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- FSQKKOOTNAMONP-UHFFFAOYSA-N acemetacin Chemical compound CC1=C(CC(=O)OCC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 FSQKKOOTNAMONP-UHFFFAOYSA-N 0.000 description 1
- 229960004892 acemetacin Drugs 0.000 description 1
- 229960000333 benzydamine Drugs 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 229960000860 dapsone Drugs 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- ZPAKPRAICRBAOD-UHFFFAOYSA-N fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 description 1
- 229960001395 fenbufen Drugs 0.000 description 1
- 229960002350 guaiazulen Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 150000002535 isoprostanes Chemical class 0.000 description 1
- YYUAYBYLJSNDCX-UHFFFAOYSA-N isoxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC=1C=C(C)ON=1 YYUAYBYLJSNDCX-UHFFFAOYSA-N 0.000 description 1
- 229950002252 isoxicam Drugs 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229960000916 niflumic acid Drugs 0.000 description 1
- 229960000965 nimesulide Drugs 0.000 description 1
- HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 229960002871 tenoxicam Drugs 0.000 description 1
- LZNWYQJJBLGYLT-UHFFFAOYSA-N tenoxicam Chemical compound OC=1C=2SC=CC=2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 LZNWYQJJBLGYLT-UHFFFAOYSA-N 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- YEZNLOUZAIOMLT-UHFFFAOYSA-N tolfenamic acid Chemical compound CC1=C(Cl)C=CC=C1NC1=CC=CC=C1C(O)=O YEZNLOUZAIOMLT-UHFFFAOYSA-N 0.000 description 1
- 229960002905 tolfenamic acid Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19661700P | 2000-04-13 | 2000-04-13 | |
| US60/196,617 | 2000-04-13 | ||
| PCT/US2001/011956 WO2001078721A1 (en) | 2000-04-13 | 2001-04-12 | Aβ42 LOWERING AGENTS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003530437A JP2003530437A (ja) | 2003-10-14 |
| JP2003530437A5 true JP2003530437A5 (https=) | 2008-05-29 |
Family
ID=22726126
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001576021A Withdrawn JP2003530437A (ja) | 2000-04-13 | 2001-04-12 | Ａβ４２低下物質 |
Country Status (6)
| Country | Link |
|---|---|
| US (5) | US6911466B2 (https=) |
| EP (1) | EP1284729A4 (https=) |
| JP (1) | JP2003530437A (https=) |
| AU (2) | AU5702201A (https=) |
| CA (1) | CA2406383A1 (https=) |
| WO (1) | WO2001078721A1 (https=) |
Families Citing this family (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060004086A1 (en) * | 2000-04-13 | 2006-01-05 | Mayo Foundation For Medical Education And Research | Method of reducing Abeta42 and treating diseases |
| JP2003530437A (ja) | 2000-04-13 | 2003-10-14 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ | Ａβ４２低下物質 |
| EP1349858B1 (en) | 2000-11-02 | 2008-08-27 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Agents useful for reducing amyloid precursor protein and treating demantia and methods of use thereof |
| WO2002038141A2 (en) * | 2000-11-08 | 2002-05-16 | Massachusetts Institute Of Technology | Compositions and methods for treatment of mild cognitive impairment |
| IL162838A0 (en) * | 2002-01-04 | 2005-11-20 | Univ Rockefeller | Compositions and methods for prevention and treatment peptide-of amyloid- related disorders |
| CA2499599A1 (en) * | 2002-09-17 | 2004-04-01 | New York University | Methods of treating age associated memory impairment (aami), mild cognitive impairment (mci), and dementias with cell cycle inhibitors |
| US7632866B2 (en) | 2002-10-21 | 2009-12-15 | Ramot At Tel Aviv University | Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators |
| WO2004035037A2 (en) * | 2002-10-21 | 2004-04-29 | Ramot At Tel Aviv University Ltd. | Derivatives of n-phenylanthranilic acid and 2-benzimidazolon as potassium channel and/or cortical neuron activity modulators |
| JP2006517925A (ja) * | 2003-01-14 | 2006-08-03 | メルク エンド カムパニー インコーポレーテッド | Ａβ４２低下薬としてのジェミナル二置換ＮＳＡＩＤ誘導体 |
| WO2004071431A2 (en) * | 2003-02-05 | 2004-08-26 | Myriad Genetics, Inc. | Method and composition for treating neurodegenerative disorders |
| ITMI20030312A1 (it) * | 2003-02-21 | 2004-08-22 | Chiesi Farma Spa | Derivati di acidi 2-fenil-2-alchil-acetici per il trattamento della malattia di alzheimer. |
| JP4472691B2 (ja) | 2003-02-21 | 2010-06-02 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | 神経変性疾患の処置のための１−フェニルアルカンカルボン酸誘導体 |
| US7521481B2 (en) | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
| WO2004087051A2 (en) * | 2003-03-27 | 2004-10-14 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
| AT413944B (de) * | 2003-05-27 | 2006-07-15 | Binder Eva Dkfm | Verwendung von oxicam-verbindungen |
| KR20060040676A (ko) * | 2003-07-11 | 2006-05-10 | 미리어드 제네틱스, 인크. | 알츠하이머병을 치료하기 위한 약제학적 방법, 투약 방법및 제형 |
| US20050171207A1 (en) * | 2003-09-26 | 2005-08-04 | Myriad Genetics, Incorporated | Method and composition for combination treatment of neurodegenerative disorders |
| SI1720909T1 (sl) * | 2004-02-23 | 2012-01-31 | Lilly Co Eli | Anti-abeta protitelo |
| WO2005092062A2 (en) * | 2004-03-19 | 2005-10-06 | Myriad Genetics, Inc. | Compounds for neurodegenerative disorders |
| WO2006001877A2 (en) * | 2004-04-13 | 2006-01-05 | Myriad Genetics, Inc. | Combination treatment for neurodegenerative disorders comprising r-flurbiprofen |
| AU2005241023A1 (en) * | 2004-04-29 | 2005-11-17 | Keystone Retaining Wall Systems, Inc. | Veneers for walls, retaining walls and the like |
| GB0410238D0 (en) * | 2004-05-07 | 2004-06-09 | Merck Sharp & Dohme | Therapeutic agents |
| EP1604970A1 (en) * | 2004-05-19 | 2005-12-14 | Cellzome Ag | 2-(Biphenyl-3-yl)-carboxylic acids of gamma-secretase-modulating activity |
| WO2005110422A2 (en) | 2004-05-19 | 2005-11-24 | Boehringer Ingelheim International Gmbh | Treatment of diseases associated with altered level of amyloid beta peptides |
| WO2005110963A1 (en) * | 2004-05-19 | 2005-11-24 | Cellzome Ag | (biphenyl-3-yl)-carboxylic acids and derivatives thereof and their use in therapy |
| WO2006020850A2 (en) * | 2004-08-11 | 2006-02-23 | Myriad Genetics, Inc. | Pharmaceutical composition and method for treating neurodegenerative disorders |
| WO2006020852A2 (en) * | 2004-08-11 | 2006-02-23 | Myriad Genetics, Inc. | Pharmaceutical composition and method for treating neurodegenerative disorders |
| BRPI0514303A (pt) * | 2004-08-11 | 2008-06-10 | Myriad Genetics Inc | composição farmacêutica e método para tratar distúrbios neurodegenerativos |
| EP1650183A1 (en) * | 2004-10-21 | 2006-04-26 | Cellzome Ag | (Benzyloxy-biphenyl) acetic acids and derivatives thereof and their use in therapy |
| EP1657232A1 (en) * | 2004-11-05 | 2006-05-17 | Cellzome Ag | Use of S-enantiomers of alpha-sustituted aryl acetic acids for the prevention of Alzheimer's disease |
| US20060241038A1 (en) * | 2005-04-20 | 2006-10-26 | Eisai Co., Ltd. | Therapeutic agent for Abeta related disorders |
| EP1876900A4 (en) * | 2005-05-02 | 2009-06-24 | Univ Columbia | PHOSPHOINOSITIDE MODULATION FOR TREATING ALZHEIMER'S DISEASE |
| CA2609980C (en) * | 2005-05-27 | 2015-10-13 | Queen's University At Kingston | Treatment of protein folding disorders |
| EP1746092A1 (en) | 2005-07-22 | 2007-01-24 | Exonhit Therapeutics SA | Compounds and methods for treatment of amyloid-B-peptide related disorders |
| CA2615063A1 (en) * | 2005-07-22 | 2007-02-01 | Myriad Genetics, Inc. | High drug load formulations and dosage forms |
| US20070179123A1 (en) * | 2005-11-08 | 2007-08-02 | Chiang Peter K | Methods and compositions for treating diseases associated with pathogenic proteins |
| ES2333539T3 (es) | 2006-04-21 | 2010-02-23 | Cellzome Limited | Derivados de terfenilo para el tratamiento de la enfermedad de alzheimer. |
| SI1849762T1 (sl) | 2006-04-21 | 2009-12-31 | Cellzome Ltd | Substituirane bifenil karboksilne kisline in derivati le-teh |
| WO2007141926A1 (ja) * | 2006-06-02 | 2007-12-13 | Osaka University | 延長型アミロイドβ産生抑制剤 |
| WO2008006099A2 (en) * | 2006-07-07 | 2008-01-10 | Myriad Genetics, Inc. | Treatment of psychiatric disorders |
| US20100173960A1 (en) * | 2006-09-21 | 2010-07-08 | Antonio Cruz | The Combination of a Cyclohexanehexol and a NSAID for the Treatment of Neurodegenerative Diseases |
| JP5317405B2 (ja) * | 2006-10-03 | 2013-10-16 | 知之 西崎 | 脳機能の改善剤及びそのスクリーニング方法 |
| CA2676715A1 (en) | 2007-02-12 | 2008-08-21 | Merck & Co., Inc. | Piperazine derivatives for treatment of ad and related conditions |
| EA016887B1 (ru) | 2007-03-07 | 2012-08-30 | Янссен Фармацевтика Н.В. | ЗАМЕЩЁННЫЕ ФЕНОКСИАМИНОТИАЗОЛОНЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ РОДСТВЕННОГО ЭСТРОГЕНОВОМУ РЕЦЕПТОРУ РЕЦЕПТОРА-α |
| CL2008000669A1 (es) | 2007-03-07 | 2008-11-03 | Janssen Pharmaceutica Nv | Compuestos derivados de tiazolidindionas n alquiladas, moduladores del receptor alfa relacionados con estrogenos; composicion farmaceutica; y su uso para tratar enfermedades relacionadas con los huesos, cancer, sindrome metabolicos, entre otras. |
| WO2008124585A1 (en) * | 2007-04-06 | 2008-10-16 | Board Of Governors For Higher Education, State Of Rhode Island And Providence Planations | Lowering of proteins associated with alzheimer's disease by interrupting gene transcription with a small molecule |
| CN101868443A (zh) | 2007-09-20 | 2010-10-20 | 特拉维夫大学拉莫特有限公司 | N-苯基邻氨基苯甲酸衍生物及其用途 |
| US7897643B2 (en) | 2007-10-17 | 2011-03-01 | Janssen Pharmaceutica N.V. | Biphenyl carboxylic acids and derivatives thereof |
| CN101903335A (zh) | 2007-10-19 | 2010-12-01 | 詹森药业有限公司 | 连接有胺的γ-分泌酶调节剂 |
| CN101903334A (zh) * | 2007-10-19 | 2010-12-01 | 詹森药业有限公司 | Gsm中间体 |
| KR20100090265A (ko) | 2007-10-19 | 2010-08-13 | 얀센 파마슈티카 엔.브이. | γ-세크레타아제의 아미드 결합된 조절제 |
| KR101618068B1 (ko) * | 2007-10-19 | 2016-05-04 | 얀센 파마슈티카 엔.브이. | γ-세크레타아제의 탄소 결합된 조절제 |
| WO2009052126A1 (en) | 2007-10-19 | 2009-04-23 | Janssen Pharmaceutica, N.V. | PIPERIDINYL AND PIPERAZINYL MODULATORS OF γ-SECRETASE |
| US7968725B2 (en) | 2008-07-22 | 2011-06-28 | Janssen Pharmaceutica N.V. | Pyridinyl modulators of γ-secretase |
| AU2009313851A1 (en) | 2008-11-13 | 2010-05-20 | Modgene, Llc | Modification of amyloid-beta load in non-brain tissue |
| WO2010071741A1 (en) | 2008-12-16 | 2010-06-24 | Merck Sharp & Dohme Corp. | Triazole derivatives for treatment of alzheimer's disease |
| PA8854101A1 (es) | 2008-12-18 | 2010-07-27 | Ortho Mcneil Janssen Pharm | Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa |
| US9925282B2 (en) | 2009-01-29 | 2018-03-27 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
| EA019685B1 (ru) | 2009-02-06 | 2014-05-30 | Янссен Фармасьютикалз, Инк. | Новые замещенные бициклические гетероциклические соединения в качестве модуляторов гамма-секретазы |
| TWI461425B (zh) | 2009-02-19 | 2014-11-21 | Janssen Pharmaceuticals Inc | 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類 |
| BRPI1011190A8 (pt) | 2009-05-07 | 2016-11-16 | Janssen Pharmaceuticals Inc | Derivados de indazol e aza-indazol substituídos como moduladores de gama secretase |
| ES2519565T3 (es) | 2009-07-15 | 2014-11-07 | Janssen Pharmaceuticals Inc. | Derivados de triazol e imidazol sustituidos como moduladores de gamma secretasa |
| JP6166534B2 (ja) | 2009-08-05 | 2017-07-19 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 新規調節タンパク質および阻害剤 |
| EP2523949B1 (en) | 2010-01-15 | 2014-08-20 | Janssen Pharmaceuticals Inc. | Novel substituted triazole derivatives as gamma secretase modulators |
| KR101924162B1 (ko) * | 2010-03-15 | 2018-11-30 | 버지니아 커먼웰스 유니버시티 | 기도의 염증 및 이상성 점액섬모 전달의 치료법으로서의 에어로졸화 댑손 |
| CA2827969A1 (en) | 2011-03-24 | 2012-09-27 | Janssen Pharmaceuticals, Inc. | Novel substituted triazolyl piperazine and triazolyl piperidine derivatives as gamma secretase modulators |
| JP2014517813A (ja) * | 2011-04-01 | 2014-07-24 | サザン リサーチ インスティテュート | スリンダク誘導体、その使用及びその調製 |
| TWI567079B (zh) | 2011-07-15 | 2017-01-21 | 健生醫藥公司 | 作為伽瑪分泌酶調節劑之新穎的經取代的吲哚衍生物 |
| EP2586436A1 (en) * | 2011-10-31 | 2013-05-01 | Commissariat à l'Énergie Atomique et aux Énergies Alternatives | Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitor |
| CA2853961C (en) | 2011-11-01 | 2016-09-20 | Modgene, Llc | Compositions and methods for reduction of amyloid-beta load |
| NZ702611A (en) | 2012-05-16 | 2016-10-28 | Cellzome Ltd | Substituted 3, 4 - dihydro - 2h - pyrido [1, 2 -a] pyrazine - 1, 6 - dione derivatives useful for the treatment of (inter alia) alzheimer’s disease |
| EP2687528A1 (en) | 2012-07-17 | 2014-01-22 | Ares Trading S.A. | Fused triazole derivatives as gamma secretase modulators |
| US10058530B2 (en) | 2012-10-25 | 2018-08-28 | The General Hospital Corporation | Combination therapies for the treatment of Alzheimer's disease and related disorders |
| EP3563849A3 (en) | 2012-10-25 | 2020-02-12 | The General Hospital Corporation | Combination therapies for the treatment of alzheimer's disease and related disorders |
| US9649360B2 (en) * | 2012-12-19 | 2017-05-16 | Shiga University Of Medical Science | Pharmaceutical composition for the treatment and/or prevention of disease involving abnormal accumulation of amyloid β protein |
| AU2013366668B2 (en) | 2012-12-20 | 2017-07-20 | Janssen Pharmaceutica Nv | Novel tricyclic 3,4-dihydro-2H-pyrido[1,2-alpha]pyrazine -1,6-dione derivatives as gamma secretase modulators |
| ES2612215T3 (es) | 2013-01-17 | 2017-05-12 | Janssen Pharmaceutica, N.V. | Novedosos derivados de pirido-piperazinona sustituidos como moduladores de gamma secretasa |
| US10525005B2 (en) | 2013-05-23 | 2020-01-07 | The General Hospital Corporation | Cromolyn compositions and methods thereof |
| CA2923835C (en) * | 2013-09-11 | 2022-11-29 | The Administrators Of The Tulane Educational Fund | Novel anthranilic amides and the use thereof |
| CN110305095A (zh) | 2013-10-22 | 2019-10-08 | 综合医院公司 | 色甘酸衍生物以及成像和治疗的相关方法 |
| US10562897B2 (en) | 2014-01-16 | 2020-02-18 | Janssen Pharmaceutica Nv | Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators |
| CN103976989A (zh) * | 2014-05-29 | 2014-08-13 | 崔德华 | 氨苯砜在制备α-分泌酶增强中的应用 |
| CA3007641C (en) | 2015-12-09 | 2023-10-17 | Brandeis University | Dbh inhibitors for treating or preventing memory loss |
| JP2019525176A (ja) * | 2016-07-28 | 2019-09-05 | アウリン バイオテック インコーポレイテッド | アルツハイマー病についての予後指標としての唾液中Ａｂｅｔａ４２レベル |
| JP2019524865A (ja) | 2016-08-31 | 2019-09-05 | ザ ジェネラル ホスピタル コーポレイション | 神経変性疾患と関連する神経炎症におけるマクロファージ／ミクログリア |
| JP7202376B2 (ja) | 2017-07-20 | 2023-01-11 | エーゼットセラピーズ， インコーポレイテッド | クロモリンナトリウムおよびイブプロフェンの粉末製剤 |
| AU2019299347A1 (en) | 2018-07-02 | 2021-01-21 | Aztherapies, Inc. | Powdered formulations of cromolyn sodium and alpha-lactose |
| MX2021006869A (es) | 2018-12-10 | 2021-07-02 | Massachusetts Gen Hospital | Esteres de cromolin y usos de los mismos. |
| WO2021207060A1 (en) | 2020-04-06 | 2021-10-14 | The General Hospital Corporation | Methods of treatment of coronavirus-induced inflammation conditions |
| WO2022146914A1 (en) | 2020-12-28 | 2022-07-07 | The General Hospital Corporation | Cromolyn derivatives and uses thereof |
| KR102784009B1 (ko) * | 2021-01-28 | 2025-03-20 | 닥터노아바이오텍 주식회사 | 콜린에스터라제 억제제 및 항산화제를 포함하는 뇌질환 치료용 약학적 복합 조성물 |
| CN118221668A (zh) * | 2024-03-19 | 2024-06-21 | 华南农业大学 | 一种含2-氨基-1,3,4-噻二唑的吲哚美辛衍生物及其制备方法和应用 |
Family Cites Families (106)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1091403A (en) * | 1964-01-24 | 1967-11-15 | Boots Pure Drug Co Ltd | Therapeutically active phenylalkane derivatives |
| FR1546478A (fr) * | 1967-01-27 | 1968-11-22 | Rhone Poulenc Sa | Nouveaux dérivés de l'acide benzoyl-3 phénylacétique et leur préparation |
| US4314081A (en) * | 1974-01-10 | 1982-02-02 | Eli Lilly And Company | Arloxyphenylpropylamines |
| NL7503310A (nl) * | 1975-03-20 | 1976-09-22 | Philips Nv | Verbindingen met antidepressieve werking. |
| GB1526331A (en) * | 1976-01-14 | 1978-09-27 | Kefalas As | Phthalanes |
| US4089969A (en) * | 1976-07-14 | 1978-05-16 | Syntex (U.S.A.) Inc. | 5-Aroyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid derivatives and process for the production thereof |
| US4209638A (en) * | 1977-03-08 | 1980-06-24 | The Boots Company Limited | Preparation of therapeutic agents |
| US4536518A (en) * | 1979-11-01 | 1985-08-20 | Pfizer Inc. | Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine |
| US4444784A (en) * | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
| US4337273A (en) * | 1980-05-15 | 1982-06-29 | Thomas Jefferson University | Methods of increasing coronary blood flow through vasodilation by flurbiprofen |
| DK149080C (da) * | 1980-06-06 | 1986-07-28 | Sankyo Co | Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre |
| US4522811A (en) * | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4686237A (en) * | 1984-07-24 | 1987-08-11 | Sandoz Pharmaceuticals Corp. | Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof |
| US4647576A (en) * | 1984-09-24 | 1987-03-03 | Warner-Lambert Company | Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis |
| IL74497A (en) * | 1985-03-05 | 1990-02-09 | Proterra Ag | Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives |
| US4668794A (en) * | 1985-05-22 | 1987-05-26 | Sandoz Pharm. Corp. | Intermediate imidazole acrolein analogs |
| DE3682136D1 (de) * | 1985-07-31 | 1991-11-28 | Hoechst Ag | N-substituierte 5-nitroanthranilsaeuren, verfahren zu ihrer herstellung, ihre verwendung sowie pharmazeutische praeparate auf basis dieser verbindungen. |
| EP0223403B1 (en) * | 1985-10-25 | 1993-08-04 | Beecham Group Plc | Piperidine derivative, its preparation, and its use as medicament |
| US4663318A (en) * | 1986-01-15 | 1987-05-05 | Bonnie Davis | Method of treating Alzheimer's disease |
| GB8601204D0 (en) * | 1986-01-18 | 1986-02-19 | Boots Co Plc | Therapeutic agents |
| WO1987004618A1 (en) * | 1986-01-30 | 1987-08-13 | University Of Utah | Treatment of bone loss |
| NL195004C (nl) * | 1987-03-04 | 2003-11-04 | Novartis Ag | Fenylcarbamaat bevattend farmaceutisch preparaat. |
| FI95572C (fi) * | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
| US5002935A (en) * | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
| DE3824353A1 (de) * | 1988-07-19 | 1990-01-25 | Paz Arzneimittelentwicklung | Verfahren zur trennung von gemischen enantiomerer arylpropionsaeuren |
| JPH0248526A (ja) * | 1988-08-08 | 1990-02-19 | Sumitomo Pharmaceut Co Ltd | インドメタシン注射剤およびその製造方法 |
| US5334618A (en) * | 1991-04-04 | 1994-08-02 | The Children's Medical Center Corporation | Method of preventing NMDA receptor-mediated neuronal damage |
| CA1340994C (en) * | 1989-09-21 | 2000-05-16 | Rudolf Edgar Dr. Falk | Treatment of conditions and disease |
| US5213738A (en) * | 1990-05-15 | 1993-05-25 | L. Perrigo Company | Method for making a capsule-shaped tablet |
| ES2217250T3 (es) * | 1990-06-15 | 2004-11-01 | Scios Inc. | Mamifero transgenico, no humano que muestra la patologia de formacion amiloides de la enfermedad de alzheimer. |
| US5015764A (en) * | 1990-06-18 | 1991-05-14 | Ethyl Corporation | Preparation of optically active aliphatic carboxylic acids |
| DE4028906A1 (de) * | 1990-09-12 | 1992-03-19 | Paz Arzneimittelentwicklung | Arzneimittel sowie deren herstellung und deren verwendung bei der bekaempfung von schmerzen und/oder entzuendungen und/oder fieber an tieren und menschen |
| US5177080A (en) * | 1990-12-14 | 1993-01-05 | Bayer Aktiengesellschaft | Substituted pyridyl-dihydroxy-heptenoic acid and its salts |
| US6746678B1 (en) * | 1991-02-22 | 2004-06-08 | Howard K. Shapiro | Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments |
| DE69206306T2 (de) * | 1991-04-08 | 1996-06-13 | Sumitomo Chemical Co | Optisch aktive Sekundär-Aminverbindung, Verfahren zur Herstellung einer optisch aktiven Sekundär-Aminverbindung und Verfahren zur Herstellung optisch aktiver Carbonsäure durch die Verwendung dieser Verbindung. |
| US5192753A (en) * | 1991-04-23 | 1993-03-09 | Mcgeer Patrick L | Anti-rheumatoid arthritic drugs in the treatment of dementia |
| US5235100A (en) * | 1992-01-24 | 1993-08-10 | Ethyl Corporation | Preparation of optically active aliphatic carboxylic acids |
| US5331000A (en) * | 1992-03-09 | 1994-07-19 | Sepracor Inc. | Antipyretic and analgesic methods and compositions containing optically pure R(-) ketoprofen |
| US5441870A (en) * | 1992-04-15 | 1995-08-15 | Athena Neurosciences, Inc. | Methods for monitoring cellular processing of β-amyloid precursor protein |
| US5455169A (en) | 1992-06-04 | 1995-10-03 | Alzheimer's Institute Of America, Inc. | Nucleic acids for diagnosing and modeling Alzheimer's disease |
| DE69324684T2 (de) * | 1992-06-30 | 1999-11-25 | Procter & Gamble Pharmaceuticals, Inc. | Arzneimitteln zur behandlung von arthritis die phosphonate und nsaids enthalten |
| IT1256450B (it) * | 1992-11-26 | 1995-12-05 | Soldato Piero Del | Esteri nitrici con attivita' farmacologica e procedimento per la loro preparazione |
| CA2150355C (en) * | 1992-12-02 | 2008-03-11 | Robert Hardy | Process of resolving phenylpropionic acids using alpha-methylbenzylamine |
| US5380867A (en) * | 1992-12-02 | 1995-01-10 | Hoechst Celanese Corporation | Selective precipitation of α-aryl carboxylic acid salts |
| US5382591A (en) * | 1992-12-17 | 1995-01-17 | Sepracor Inc. | Antipyretic and analgesic methods using optically pure R-ketorolac |
| GB9314693D0 (en) * | 1993-07-15 | 1993-08-25 | Smithkline Beecham Plc | Naphthyl derivatives for treatment method |
| CA2128820A1 (en) * | 1993-07-27 | 1995-01-28 | Walter G. Gowan, Jr. | Rapidly disintegrating pharmaceutical dosage form and process for preparation thereof |
| US5541231A (en) * | 1993-07-30 | 1996-07-30 | Glaxo Wellcome Inc. | Stabilized Pharmaceutical |
| GB9315856D0 (en) * | 1993-07-30 | 1993-09-15 | Wellcome Found | Stabilized pharmaceutical |
| US5434170A (en) * | 1993-12-23 | 1995-07-18 | Andrulis Pharmaceuticals Corp. | Method for treating neurocognitive disorders |
| GB9403857D0 (en) * | 1994-03-01 | 1994-04-20 | Scotia Holdings Plc | Fatty acid derivatives |
| US5574022A (en) * | 1994-04-14 | 1996-11-12 | The Center For Innovative Technology | Method of attenuating physical damage to the spinal cord |
| US5643960A (en) * | 1994-04-15 | 1997-07-01 | Duke University | Method of delaying onset of alzheimer's disease symptoms |
| US6025395A (en) * | 1994-04-15 | 2000-02-15 | Duke University | Method of preventing or delaying the onset and progression of Alzheimer's disease and related disorders |
| EP0714663A3 (en) * | 1994-11-28 | 1997-01-15 | Lilly Co Eli | Potentiation of drug responses by serotonin 1A receptor antagonists |
| US5518738A (en) * | 1995-02-09 | 1996-05-21 | Nanosystem L.L.C. | Nanoparticulate nsaid compositions |
| US5935860A (en) * | 1995-03-07 | 1999-08-10 | The George Washington University | Use of uteroglobin expression as a molecular marker for prostatic intraepithelial neoplasia |
| US5626838A (en) * | 1995-03-13 | 1997-05-06 | The Procter & Gamble Company | Use of ketorolac for treatment of squamous cell carcinomas of the oral cavity or oropharynx |
| US6160018A (en) * | 1995-03-13 | 2000-12-12 | Loma Linda University Medical Center | Prophylactic composition and method for alzheimer's Disease |
| US5703073A (en) * | 1995-04-19 | 1997-12-30 | Nitromed, Inc. | Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs |
| US5750564A (en) * | 1995-09-12 | 1998-05-12 | Hellberg; Mark | Anti-oxidant esters of non-steroidal anti-inflammatory agents |
| US5897880A (en) * | 1995-09-29 | 1999-04-27 | Lam Pharmaceuticals, Llc. | Topical drug preparations |
| GB9523833D0 (en) * | 1995-11-22 | 1996-01-24 | Boots Co Plc | Medical treatment |
| IT1277741B1 (it) * | 1995-12-28 | 1997-11-12 | Dompe Spa | Composizioni farmaceutiche parenterali contenenti sali di alchilammonio di acidi 2-arilpropionici |
| SE9600070D0 (sv) * | 1996-01-08 | 1996-01-08 | Astra Ab | New oral pharmaceutical dosage forms |
| US6231888B1 (en) * | 1996-01-18 | 2001-05-15 | Perio Products Ltd. | Local delivery of non steroidal anti inflammatory drugs (NSAIDS) to the colon as a treatment for colonic polyps |
| TW506836B (en) * | 1996-06-14 | 2002-10-21 | Janssen Pharmaceutica Nv | Fast-dissolving galanthamine hydrobromide tablet |
| WO1997048391A2 (en) * | 1996-06-21 | 1997-12-24 | Advanced Research And Technology Institute | Methods and compositions comprising r-ibuprofen |
| US6184248B1 (en) * | 1996-09-05 | 2001-02-06 | Robert K. K. Lee | Compositions and methods for treatment of neurological disorders and neurodegenerative diseases |
| US6043224A (en) * | 1996-09-05 | 2000-03-28 | The Massachusetts Institute Of Technology | Compositions and methods for treatment of neurological disorders and neurodegenerative diseases |
| HRP970485A2 (en) * | 1996-09-13 | 1998-08-31 | Joerg Rosenberg | Process for producing solid pharmaceutical forms |
| US5898094A (en) * | 1996-10-21 | 1999-04-27 | University Of South Florida | Transgenic mice expressing APPK670N,M671L and a mutant presenilin transgenes |
| US5858738A (en) * | 1996-11-07 | 1999-01-12 | Merck & Co., Inc. | Ermophilane sesquiterpenoids as HIV intergrase inhibitors |
| AU5727798A (en) * | 1996-12-23 | 1998-07-17 | Texas A & M University, The | Anti-amyloidogenic agents |
| WO1998040061A1 (en) * | 1997-03-10 | 1998-09-17 | Loma Linda University Medical Center | Use of r-nsaid's for the prevention of alzheimer's disease |
| GB9710521D0 (en) * | 1997-05-22 | 1997-07-16 | Boots Co Plc | Process |
| ES2218869T3 (es) * | 1997-12-05 | 2004-11-16 | Eisai Co., Ltd. | Cristales polimorficos de donepezil y un proceso para produccion de dichos cristales. |
| US6365180B1 (en) * | 1998-01-20 | 2002-04-02 | Glenn A. Meyer | Oral liquid compositions |
| CA2319131A1 (en) * | 1998-01-26 | 1999-07-29 | Walter H. Moos | Mitochondria protecting agents for treating mitochondria associated diseases |
| IT1298214B1 (it) * | 1998-01-28 | 1999-12-20 | Dompe Spa | Sali dell'acido (r) 2-(3-benzoilfenil) propionico e loro composizioni farmaceutiche. |
| US6051587A (en) * | 1998-04-16 | 2000-04-18 | Medicure, Inc. | Treatment of iatrogenic and age-related hypertension and pharmaceutical compositions useful therein |
| US6054451A (en) * | 1998-04-21 | 2000-04-25 | Algos Pharmaceutical Corporation | Analgesic composition and method for alleviating pain |
| US6160618A (en) * | 1998-06-19 | 2000-12-12 | Board Of Regents, The University Of Texas System | Hyperspectral slide reader |
| WO2000013684A2 (en) * | 1998-09-03 | 2000-03-16 | Loma Linda University Medical Center | Pharmaceutical composition and method for treatment of inflammation |
| US6297260B1 (en) * | 1998-10-30 | 2001-10-02 | Nitromed, Inc. | Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use |
| IN189741B (https=) * | 1998-11-09 | 2003-04-19 | Council Scient Ind Res | |
| CA2350531A1 (en) * | 1998-11-13 | 2000-05-25 | Smriti Iyengar | Method for treating pain |
| US6726929B1 (en) * | 1998-12-18 | 2004-04-27 | Basf Aktiengesellschaft | Pharmaceutical mixture comprising a profen |
| US6383527B1 (en) * | 1999-03-04 | 2002-05-07 | Nps Pharmaceuticals, Inc. | Compositions comprising valerian extracts, isovaleric acid or derivatives thereof with a NSAID |
| ES2251985T3 (es) * | 1999-03-24 | 2006-05-16 | R.P. Scherer Technologies, Inc. | Particula granulada para mejorar la solubilidad acuosa de farmacos, y su procedimiento de preparacion. |
| ATE254928T1 (de) * | 1999-03-31 | 2003-12-15 | Eisai Co Ltd | Stabilisierte zusammensetzung mit nootropen wirkstoffen |
| US6383471B1 (en) * | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
| US6368618B1 (en) * | 1999-07-01 | 2002-04-09 | The University Of Georgia Research Foundation, Inc. | Composition and method for enhanced transdermal absorption of nonsteroidal anti-inflammatory drugs |
| US20060004086A1 (en) * | 2000-04-13 | 2006-01-05 | Mayo Foundation For Medical Education And Research | Method of reducing Abeta42 and treating diseases |
| JP2003530437A (ja) * | 2000-04-13 | 2003-10-14 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ | Ａβ４２低下物質 |
| US6355666B1 (en) * | 2000-06-23 | 2002-03-12 | Medinox, Inc. | Protected forms of pharmacologically active agents and uses therefor |
| EP1303265B1 (en) * | 2000-07-20 | 2007-07-11 | Lauras AS | Use of cox-2 inhibitors as immunostimulants in the treatment of hiv or aids |
| DE10047319A1 (de) * | 2000-09-25 | 2002-04-18 | Paz Arzneimittelentwicklung | Verwendung von R-Arylpropionsäuren zur Herstellung von Arzneimitteln zur Behandlung von Erkrankungen, welche durch die Hemmung der Aktivierung des nukleären Transkriptionsfaktors AP-1 therapeutisch beeinflußt werden können |
| US20030027867A1 (en) * | 2001-06-29 | 2003-02-06 | Myriad Genetics, Incorporated | Use of R-NSAID compounds for anti-HIV treatment |
| US20040049134A1 (en) * | 2002-07-02 | 2004-03-11 | Tosaya Carol A. | System and methods for treatment of alzheimer's and other deposition-related disorders of the brain |
| WO2004032845A2 (en) * | 2002-10-07 | 2004-04-22 | Encore Pharmaceuticals, Inc. | R-nsaid esters and their use |
| JP4472691B2 (ja) * | 2003-02-21 | 2010-06-02 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | 神経変性疾患の処置のための１−フェニルアルカンカルボン酸誘導体 |
| KR20060040676A (ko) * | 2003-07-11 | 2006-05-10 | 미리어드 제네틱스, 인크. | 알츠하이머병을 치료하기 위한 약제학적 방법, 투약 방법및 제형 |
| US20070015832A1 (en) * | 2005-07-14 | 2007-01-18 | Myriad Genetics, Incorporated | Methods of treating overactive bladder and urinary incontinence |
| CA2615063A1 (en) * | 2005-07-22 | 2007-02-01 | Myriad Genetics, Inc. | High drug load formulations and dosage forms |
| US20070078114A1 (en) * | 2005-09-02 | 2007-04-05 | Myriad Genetics, Incorporated | Combination therapy for alzheimer's disease and other diseases |
-
2001
- 2001-04-12 JP JP2001576021A patent/JP2003530437A/ja not_active Withdrawn
- 2001-04-12 EP EP01930491A patent/EP1284729A4/en not_active Withdrawn
- 2001-04-12 CA CA002406383A patent/CA2406383A1/en not_active Abandoned
- 2001-04-12 AU AU5702201A patent/AU5702201A/xx active Pending
- 2001-04-12 AU AU2001257022A patent/AU2001257022B2/en not_active Ceased
- 2001-04-12 WO PCT/US2001/011956 patent/WO2001078721A1/en not_active Ceased
- 2001-12-07 US US10/012,606 patent/US6911466B2/en not_active Expired - Fee Related
-
2004
- 2004-08-27 US US10/928,925 patent/US7097998B2/en not_active Expired - Fee Related
-
2005
- 2005-04-25 US US11/113,789 patent/US20050186559A1/en not_active Abandoned
-
2007
- 2007-04-26 US US11/740,800 patent/US20070253906A1/en not_active Abandoned
- 2007-04-26 US US11/740,791 patent/US20070253905A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003530437A5 (https=) | ||
| Dionne et al. | Therapeutic uses of non-steroidal anti-inflammatory drugs in dentistry | |
| Vane et al. | New insights into the mode of action of anti-inflammatory drugs | |
| Mauleón et al. | Preclinical and clinical development of dexketoprofen | |
| Moore | Diclofenac potassium 12.5 mg tablets for mild to moderate pain and fever: a review of its pharmacology, clinical efficacy and safety | |
| Israel et al. | Aspirin and N‐acetylcysteine co‐administration markedly inhibit chronic ethanol intake and block relapse binge drinking: Role of neuroinflammation‐oxidative stress self‐perpetuation | |
| Lanas et al. | Clinical implications of COX-1 and/or COX-2 inhibition for the distal gastrointestinal tract | |
| Van Ryn et al. | Meloxicam does not affect the antiplatelet effect of aspirin in healthy male and female volunteers | |
| Ahmed et al. | Meloxicam in rheumatoid arthritis | |
| AU2008247439A1 (en) | Use of TP modulators for the treatment of cardiovascular disorders in aspirin sensitive and other populations | |
| KR20040053129A (ko) | Ｎｓａｉｄ 및 ｐｄｅ-4 억제제의 조합물 | |
| Murray et al. | Nonsteroidal anti-inflammatory drugs | |
| RU2204388C2 (ru) | ИБУПРОФЕНОВЫЙ ТИОЭФИР В КАЧЕСТВЕ ИНГИБИТОРА, ЗАВИСЯЩЕГО ОТ Nf-kB ОБРАЗОВАНИЯ МЕДИАТОРОВ ВОСПАЛЕНИЯ И БОЛИ | |
| Aprioku et al. | Renal effects of non-steroidal anti inflammatory drugs in albino rats | |
| Chan | NSAID-induced peptic ulcers and Helicobacter pylori infection: implications for patient management | |
| CA2403352C (en) | Use of comt inhibitors as analgesics | |
| NZ312997A (en) | use of a non-steroidal anti-inflammatory agent for treating colonic adenomas | |
| JP2001514655A (ja) | アルツハイマー病予防へのｒ−ｎｓａｉｄ’ｓの利用 | |
| Laudanno et al. | In vivo selectivity of nonsteroidal antiinflammatory drugs and gastrointestinal ulcers in rats | |
| Takeuchi et al. | Gastrointestinal sparing anti-inflammatory drugs-effects on ulcerogenic and healing responses | |
| RU2250103C2 (ru) | ПРИМЕНЕНИЕ (R)-АРИЛПРОПИОНОВЫХ КИСЛОТ ДЛЯ ПОЛУЧЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ЛЮДЕЙ И ЖИВОТНЫХ, НА КОТОРЫЕ МОЖНО ОКАЗЫВАТЬ ТЕРАПЕВТИЧЕСКОЕ ВОЗДЕЙСТВИЕ ПУТЕМ ИНГИБИРОВАНИЯ АКТИВАЦИИ NF-κВ | |
| JP5579958B2 (ja) | Ｃｏｘ−２インヒビターを含有する鎮痛及び抗炎症性組成物 | |
| Xin et al. | Analgesic effect of parecoxib and flurbiprofen axetil for patients undergoing laparoscopic cholecystectomy and their influences on platelet aggregation | |
| FR2953411A1 (fr) | Combinaison synergique de composes analgesiques | |
| JP2011106846A (ja) | 新規ｎｓａｉｄ潰瘍リスク判定方法 |